Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Sonelokimab Interleukin-17A and -F nanobody Treatment of moderate to severe psoriasis Treatment of hidradenitis suppurativa

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Author(s): Yao, Yiqiu; Jorgensen, Astrid-Helene Ravn; Nielsen, Valdemar Wendelboe; Egeberg, Alexander; Thyssen, Jacob P.; Thomsen, Simon Francis
  • Source:
    Yao , Y , Jorgensen , A-H R , Nielsen , V W , Egeberg , A , Thyssen , J P & Thomsen , S F 2022 , ' Sonelokimab Interleukin-17A and -F nanobody Treatment of moderate to severe psoriasis Treatment of hidradenitis suppurativa ' , Drugs of the Future , vol. 47 , no. 8 , pp. 567-573 .
  • Document Type:
    Electronic Resource
  • Online Access:
    https://researchprofiles.ku.dk/da/publications/sonelokimab-interleukin17a-and-f-nanobody-treatment-of-moderate-to-severe-psoriasis-treatment-of-hidradenitis-suppurativa(ba60ffe8-f84c-4650-838d-2a8ab5c6a38a).html
    https://doi.org/10.1358/dof.2022.47.8.3435135
  • Additional Information
    • Publisher Information:
      2022-08
    • Abstract:
      Psoriasis is a common, chronic inflammatory disease characterized by sustained inflammation and hyperproliferation of epidermal keratinocytes. With the establishment of the interleukin (IL)-17/IL-23 pathway as a principal player in the etiopathogenesis of psoriasis, and the subsequent development of anti-IL-17/IL-23 biologics, targeted treatment for psoriasis has significantly improved within the past decade. Currently, 4 IL-17 inhibitors are approved for the treatment of moderate to severe plaque psoriasis in adults-secukinumab, ixekizumab, brodalumab and bimekizumab-all of which are monoclonal antibodies. In this scoping review article, we present the current literature on sonelokimab, a novel anti-IL-17A/F nanobody for the treatment of moderate to severe psoriasis.
    • Subject Terms:
      IL-17; Monoclonal antibody; Nanobody; Psoriasis; Sonelokimab; M-1095; SEVERE PLAQUE PSORIASIS; DOUBLE-BLIND; MULTICENTER; EFFICACY; SAFETY; BIMEKIZUMAB; MECHANISMS; FAMILY; SHARK; article
    • Availability:
      Open access content. Open access content
      info:eu-repo/semantics/closedAccess
    • Note:
      English
    • Other Numbers:
      DAV oai:pure.atira.dk:publications/ba60ffe8-f84c-4650-838d-2a8ab5c6a38a
      1349071437
    • Contributing Source:
      UNIV OF COPENHAGEN
      From OAIster®, provided by the OCLC Cooperative.
    • Accession Number:
      edsoai.on1349071437
HoldingsOnline